- Home
- NRXS vs CMMB Comparison
NRXS vs CMMB Comparison
Compare NRXS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- CMMB
- Stock Information
- Founded
- NRXS 2011
- CMMB 2004
- Country
- NRXS United States
- CMMB Israel
- Employees
- NRXS N/A
- CMMB N/A
- Industry
- NRXS
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- CMMB Health Care
- Exchange
- NRXS Nasdaq
- CMMB Nasdaq
- Market Cap
- NRXS 25.0M
- CMMB 22.0M
- IPO Year
- NRXS 2023
- CMMB N/A
- Fundamental
- Price
- NRXS $2.43
- CMMB $3.09
- Analyst Decision
- NRXS Strong Buy
- CMMB Strong Buy
- Analyst Count
- NRXS 1
- CMMB 2
- Target Price
- NRXS $7.00
- CMMB $26.50
- AVG Volume (30 Days)
- NRXS 52.6K
- CMMB 136.3K
- Earning Date
- NRXS 08-12-2025
- CMMB 08-14-2025
- Dividend Yield
- NRXS N/A
- CMMB N/A
- EPS Growth
- NRXS N/A
- CMMB N/A
- EPS
- NRXS N/A
- CMMB N/A
- Revenue
- NRXS $3,217,531.00
- CMMB N/A
- Revenue This Year
- NRXS $62.14
- CMMB N/A
- Revenue Next Year
- NRXS $131.87
- CMMB N/A
- P/E Ratio
- NRXS N/A
- CMMB N/A
- Revenue Growth
- NRXS 41.93
- CMMB N/A
- 52 Week Low
- NRXS $1.33
- CMMB $2.99
- 52 Week High
- NRXS $6.20
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- NRXS 46.52
- CMMB 24.58
- Support Level
- NRXS $2.35
- CMMB $2.99
- Resistance Level
- NRXS $2.68
- CMMB $3.86
- Average True Range (ATR)
- NRXS 0.13
- CMMB 0.26
- MACD
- NRXS 0.01
- CMMB -0.02
- Stochastic Oscillator
- NRXS 41.59
- CMMB 8.85
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.